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Autosomal-Recessive Hypophosphatemic Rickets
Is Associated with an Inactivation Mutation
in the ENPP1 Gene
Varda Levy-Litan,1,9 Eli Hershkovitz,2,9 Luba Avizov,1 Neta Leventhal,2 Dani Bercovich,3
Vered Chalifa-Caspi,4 Esther Manor,1,5,6 Sophia Buriakovsky,1 Yair Hadad,7 James Goding,8
and Ruti Parvari1,4,*
Human disorders of phosphate (Pi) handling and hypophosphatemic rickets have been shown to result frommutations in PHEX, FGF23,
and DMP1, presenting as X-linked recessive, autosomal-dominant, and autosomal-recessive patterns, respectively. We present the iden-
tiﬁcation of an inactivating mutation in the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene causing autosomal-
recessive hypophosphatemic rickets (ARHR) with phosphaturia by positional cloning. ENPP1 generates inorganic pyrophosphate
(PPi), an essential physiologic inhibitor of calciﬁcation, and previously described inactivating mutations in this gene were shown to
cause aberrant ectopic calciﬁcation disorders, whereas no aberrant calciﬁcations were present in our patients. Our surprising result
suggests a different pathway involved in the generation of ARHR and possible additional functions for ENPP1.Human disorders of phosphate (Pi) handling and hypo-
phosphatemic rickets have been shown to result from
mutations in PHEX (MIM 300550),1 FGF23 (MIM
605380),2 and DMP1 (MIM 600980),3,4 presenting as
X-linked recessive (XLH [MIM 307800]), autosomal-domi-
nant (ADHR [MIM 193100]), and autosomal-recessive
patterns (ARHR [MIM 241520]), respectively. These genes
have been proposed to act in a common pathway.5
The studied pedigree (Figure 1A) was of a family of
Bedouin origin. The study was approved by the Soroka
Medical University Center institutional review boards,
and all patients gave written informed consent before
participating.
Patient III1 was referred to the pediatric endocrinology
clinic for evaluation of bowing legs at 10 yrs of age. On
physical examination, short stature (< 3rd percentile for
age), mild dental carries, slight widening of the wrist,
and signiﬁcant valgum deformity of the knee (genu val-
gum) (Figures S1A and S1B, available online) were noted.
He was found to have hypophosphatemia, hyperphospha-
turia, elevated plasma alkaline phosphatase, normal levels
of serum calcium, normal calcium excretion, PTH and
vitamin D metabolites (25OH and 1,25 (OH)2), consistent
with hypophosphatemic rickets (Table 1). The patient was
treated by phosphates and vitamin D supplements. The
response to treatment was inconsistent, and despite wedge
osteotomies of the femurs and tibias, the valgum defor-
mity of the knee recurred.
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The Americashort stature at 9 yrs of age. Short stature (<3rd percentile
for age), hypoplastic teeth and caries, slight widening of
the wrist, and mild genu valgum were noted. X-rays of
his left hand revealed delayed bone age and signs of rickets
(Figure S1C). Laboratory evaluation conﬁrmed the diag-
nosis of hypophosphatemic rickets. The abovementioned
therapy was offered, but the effect on serum Pi and height
was poor. He underwent bilateral wedge osteotomies of the
distal femurs, with current successful correction of his
deformity.
Patient III4 was examined with the rest of the family
members as part of this research project. The patient has
normal stature and was apparently healthy except for
limping due to delayed healing of a posttraumatic (road
accident) fracture of his left distal tibia that occurred
2.5 yrs earlier, requiring several orthopedic operations.
Laboratory evaluation disclosed hypophosphatemia and
hyperphosphaturia.
Renal function was normal in all patients, and no
tubular dysfunction (except for phosphaturia) has been
demonstrated. We found no evidence of vascular or periar-
ticular calciﬁcations in X-ray ﬁlms of the chest, abdomen,
and lower limbs of the patients or in abdominal CT of
patient III4 (taken after the road accident).
The rest of the family members (parents and siblings)
were found to be healthy, without any abnormal clinical
or laboratory ﬁndings.
Serum FGF23 levels, measured in three experiments with
the Elisa Kit of Kainos (Japan) to the full-length biologi-
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Figure 1. Identification of the Y901S Mutation at the Evolutionarily Conserved Y901 Amino Acid
(A) Haplotype analysis based on microsatellite markers from 6q revealed a founder haplotype (black bar) for which the patient is homo-
zygous in the critical region harboring the ENPP1 gene. The numbers of the patients correspond to those present in Table 1.
(B) Sequence of the corresponding c.A2722C mutation resulting in Y901S. Patients were homozygous for the mutation, parents
and siblings carrying the founder haplotype were heterozygous, and the healthy siblings without the founder haplotype were
normal.
(C) Evolutionary conservation of the replaced amino acid Y901. Multiple sequence alignment was carried out by ClustalW. S repre-
sents the mutation. Asterisk (*), identical; colon (:), strictly conserved.patients and were somewhat higher in one patient. This
resembles the ﬁndings in both XLH patients and patients
withmutations in DMP1, in which not all patients showed
elevated FGF23 levels.3,4,6274 The American Journal of Human Genetics 86, 273–278, FebruaryAfter linkage to PHEX, FGF23, and DMP1 was excluded,
we searched for homozygous regions consistent with
linkage by genotyping the three patients and a parent
with the Affymetrix (CA, USA) GeneChip Human12, 2010
Table 1. Clinical and Biochemical Data of ARHR Patients
Patient III1 Patient III11 Patient III4 Ref. Range
Age (yrs) 19 16 30
Height (cm) 152 143 165
Ca (mmol/l) 2.4 2.32 2.45 2.1–2.6
Pi (mmol/l) 0.77 0.68 0.65 0.95–1.75
AP (U/l) (ref. range) 589 (130–350) 480 (150–480) 95 (65–200)
PTH (pg/ml) 38 18 59 10–65
25OHD (ng/ml) 29 23 34 20–45
1,25(OH)2D (pg/ml) 27 31 24 19–50
FGF 23 (pg/ml) 50 78 47 10–50
U Ca/Cr (mg/mg) 0.01 0.06 0.05 <0.2
TRP % 80 83 95 85–95
Tp/GFR (ref. range) 2.32 (4.2 5 0.6) 2.4 (4.2 5 0.6) 1.7 (3.2 5 0.5)
All ions and hormones were measured in serum. Ref. range, reference range. Ca, calcium; Pi, phosphate; AP, alkaline phosphatase; PTH, parathyroid hormone;
25OHD, 25 Hydroxy vitamin D; 1,25(OH)2D, 1,25 dihydroxy vitamin D; FGF 23, fibroblast growth factor 23. All were measured in serum after 12 hr fasting,
isolated within 30 min after blood withdrawal by centrifugation, and stored at 80C before biochemical analysis. Because FGF23 is cleaved between Arg179
and Ser180 and this processing abolishes the biological activity of FGF23,6 full-length FGF23 levels were measured with a commercial ELISA Kit (Kainos) containing
monoclonal antibodies to both the C and N terminus and requiring the presence of both ends for the measurement.4 U Ca/Cr, urinary calcium to creatinine ratio;
TRP %, tubular reabsorption of phosphorus; Tp/GFR, tubular phosphorus reabsorption to glomerular filtration rate ratio.Mapping 250K Nsp arrays. The genotype calls were deter-
mined with Affymetrix Genotyping Console software.
Dedicated software (KinSNP) was developed in-house to
automatically search the microarray results for homozy-
gous regions consistent with linkage. Three large homozy-
gous regions (>2 cM) were identiﬁed, and two were
excluded after testing of all family members for microsatel-
lite markers in the regions. Polymorphic markers for the
region were developed with the Tandem Repeats Finder,7
and PCR primers were designed with the use of the Primer3
website. We identiﬁed linkage to the chromosomal locus
6q23: 128,856,370–136,244,929 (NCBI Build 36.1) (Fig-
ure 1A) with a signiﬁcant LOD score of 3.45 for D6S262,
calculated with Superlink v1.4 at the PedTool server. The
calculation was done with the assumption of recessive
inheritance with 99% penetrance and an incidence of
0.01 or 0.001 for the disease allele in the population. The
multipoint analysis resulted in a LOD score of 4.27.
The linkage interval of 7.39 Mb contains 70 genes,
including the ENPP1 gene, a known player in Pi metabo-
lism.8 Total RNA was derived from lymphoblastoid cells
by the EZ-RNA Reagent (Biologic Industries, Israel). Reverse
transcriptase reaction was performed with the Reverse iT
1st Strand Synthesis Kit (ABgene). The cDNA coding region
for ENPP1 was directly sequenced on an ABI PRISM 3100
DNA Analyzer with the BigDye Terminator v. 1.1 Cycle
Sequencing Kit according to the manufacturer’s protocol
(Applied Biosystems, CA, USA). The primers that revealed
the mutation in the ENPP1 cDNA were as follows: for-
ward primer, 50-CCTCTCCCCACCACAACTAA-30; reverse
primer, 50-TCATGGTGTTTGGGGATAAAA-30.We identiﬁed
a nonsynonymous variation (NM_006208.2: c.A2722C,The AmericaNP_006199.2: p.Y901S) that presented homozygously in
all patients and segregated as expected in thehealthy family
members (Figure 1B). To exclude the possibility that this
variation represents polymorphism, we tested 236 Bedouin
control individuals of the same geographic region. The
primers designed for DNA analysis for screening of the
mutation by denaturing high-performance liquid chroma-
tography (DHPLC) ampliﬁcation of a 192 bp PCR product
were as follows: forward primer, 50-TCCTATTCTCCTAG
CATGGGAAGC-30; reverse primer, 50-AAACATATCAGTC
TTCTTGGC-30. PCR was performed with high-ﬁdelity Taq
polymerase (Fast-Start Taq, Roche). Mutation analysis was
performed with the WAVE apparatus from Transgenomic
(NE, USA). PCR products were subjected to DNA chroma-
tography.9 For identiﬁcation of the homozygousmutation,
10 ml PCR product of wild-type (WT) DNA and 10 ml PCR
product of sample DNAweremixed in a 1:1 ratio and dena-
tured at 95C. This enabled detection of the homozygous
mutation by formation of a heteroduplex.
We sought evidence for pathogenic relevance of this
variation in multiple sequence alignments of the NPP
family of proteins and evolutionary conservation. The
tyrosine in position 901 resides in the nuclease-like
domain and is strictly conserved in ENPP1 (Figure 1C),
but it is replaced by phenylalanine in ENPP2 while retain-
ing the three-dimensional structure (not shown). To the
best of our knowledge, the three-dimensional structure of
the nuclease-like domain is not yet solved; thus, the effect
of the amino acid replacement on the protein conforma-
tion could not be modeled.
To determine the functional impact of the identiﬁed vari-
ation in ENPP1, we used a previously described full-lengthn Journal of Human Genetics 86, 273–278, February 12, 2010 275
Figure 2. The Effect of the Y901S Muta-
tion and the 779P SNP
(A) ENPP1 activity in intact COS7 cells
transfected with the full-length WT
human ENPP1 cDNA (WT), the
c.A2722C (Y901S) mutated cDNA (Mut),
and the 779P variation (SNP) in pSVT7
expression vectors. Values are expressed
as the ratio of NPP activity to time,
normalized by total protein concentration
and ENPP1 protein levels to correct for
transfection efﬁciency. Untransfected
COS7 cells treated in the same way as
others served as negative controls, and
their background activity was subtracted
from the WT, Mut, and SNP activities.
ENPP1 levels were determined by immu-
noblotting and normalized to b-actin.
Values are means 5 SEM of ﬁve indepen-
dent experiments, each consisting of
triplicates of all samples (n ¼ 15). WT:
1.633 5 0.083. Mut: 0.065 5 0.302.
SNP: 2.775 5 0.282. *p ¼ 0.006.
**p ¼ 0.0002 (two-tailed Student’s t test,
a level was 0.05; data were tested for
normality by the Shapiro-Wilk test).
(B) Representative immunoblot of the ENPP1 protein of WT, Mut, SNP, and negative control. All visible bands resulting from the trans-
fection were used for the normalization to ENPP1 protein levels.
(C) Immunoﬂuorescence staining of COS7 cells transfected with WT and Mut constructs, showing similar membrane localization.
Staining performed with the 3E8 mouse monoclonal antibody13 and secondary antibody Alexa 488 goat anti-mouse IgG. Representa-
tive ﬁgures of four independent experiments, taken with the Zeiss LSM Axiovert 100 laser scanning microscope. WT scaling (resolu-
tion): X, 0.29 mm; Y, 0.29 mm; Z, 0.37 mm. Mut scaling (resolution): X, 0.29 mm; Y, 0.29 mm; Z, 0.32 mm.
(D) ENPP1 activity in lysed COS7 cells transfected with WT, Mut, and SNP constructs. Cells were mechanically lysed by passing
through a 21G syringe needle until no pellet was visible. Activity is calculated and represented as in (A). Values are means 5 SEM
of ﬁve independent experiments, each consisting of triplicates of all samples (n ¼ 15). WT: 1.653 5 0.073. Mut: 0.059 5 0.328.
SNP: 2.869 5 0.307. *p ¼ 0.0067. **p ¼ 0.0004 (Student’s t test).WT human ENPP1 cDNA construct in the pSVT7 expres-
sion vector10 to create the c.A2722C mutation, using the
QuickChange site-directed mutagenesis protocol with Bio-
exact Taq polymerase Biolab (LaJolla, CA). The primers
used for creating the mutant sequence were as follows:
mut forward primer, 50-CAGCTTCTCTCAACAAAGAAAA
GAG-30; mut reverse primer, 50-CTTTGTTGAGAGAAGCT
GAGTCC-30. COS 7 cells were transfected with themutated
and control vectors with TransIT-LT1 Transfection Reagent
(Mirus, USA), according to themanufacturer’s instructions.
Cells treated in the same way as others but without the
addition of DNA served as negative controls. Next, 48 hr
after transfection, cells were harvested with PBS, and equal
portions of about a million cells were separated for
measurement of the ENPP1 activity in intact cells, with
the use of the membrane-impermeant charged substrate
p-nitrophenyl phenyl phosphonate.11 The remainder of
cells were used for immunoblot analyses in order to
normalize ENPP1 activity according to transfection efﬁ-
ciency. Protein samples were loaded in graded concentra-
tions, assuring linearity. ENPP1 was detected with the
primary rabbit antibody R1702 against the N-terminal
cytoplasmic tail,10 followed by HRP-conjugated anti-IgG
anti-rabbit secondary antibody (Jackson ImmunoResearch,
PA, USA). To normalize for protein loading, the lower part
of the blot was cut and incubated with mouse anti b- actin276 The American Journal of Human Genetics 86, 273–278, February(Sigma, USA), followed by incubation with HRP- conju-
gated donkey anti-mouse IgG secondary antibody (Jackson
ImmunoResearch). The bound antibodies were visualized
with the EZ-ECL Kit (Biological Industries, Israel) and
subsequent exposure to X-ray ﬁlm. Densitometry was
measured with the TINA software (Raytest, Straubenhardt,
Germany). The ratio of ENPP1 to actin was used to stan-
dardize the quantiﬁcation of enzyme activity. The muta-
tion abolished NPP activity at the cell surface (Figure 2A).
We noted that the mutated ENPP1 protein migrates faster
than the normal protein (Figure 2B). ENPP1 is a glycosy-
lated ecto-enzyme, with its amino terminus in the cyto-
plasm and extracellular catalytic domains.12 The possi-
bility that the faster-migrating mutated protein does not
reach the plasma membrane was tested by immunoﬂuoro-
scence staining of intact transfected cells with the 3E8
mouse monoclonal antibody to the native form of
ENPP1,13 followed by Alexa 488-conjugated goat anti-
mouse IgG (Molecular Probes). This staining showed that
the cell-membrane localization of the mutated protein is
comparable to the WT enzyme (Figure 2C). Furthermore,
when transfected cells were mechanically lysed by passing
through a 21G needle until no pellet was visible, the
lysates showed similar relative activities in mutant and
WT sequences and enzyme activity was similar to that
seen in intact cells, suggesting that in both cases the12, 2010
majority of the enzyme was located at the cell surface
(Figure 2D).
Genetic analysis of rare disorders has identiﬁed genes
involved in common diseases.14 The ENPP1 gene resides
in a chromosomal locus that is a suggestive quantitative
trait locus for bone loss in rats.15 Thus, we hypothesized
that ENPP1 activity may have a role in this trait; Different
polymorphisms in this gene in the human populationmay
alter its enzymatic activity, which in turn will affect bone
loss, as observed in the hypophosphatemic patients. We
tested a known human SNP for its possible effect on the
enzymatic activity (rs1805138; NM_006208.2: c.A2335C;
NP_006199.2: p.Thr779Pro). The replacement of the thre-
onine by proline at position 779 in the nuclease-like
domain would be expected to result in a major change in
the three-dimensional conformation of the enzyme.
Indeed, the functional importance of the structure of this
domain is demonstrated by the signiﬁcant reduction of
enzymatic activity caused by adjacent mutations C726R,
N792S, and R774C.16 Site-directed mutagenesis was used
to create the c.A2335C replacement as above; the primers
used were as follows: T727P forward primer, 50-GACCCCC
TACTGCGAAAGTATG-30; T727P reverse primer, 50-CAGT
AGGGGGTCATGAAAGTAGC-30. The T779P change intro-
duced into the pSVT7 expression vector harboring the full-
length ENPP1 resulted in a signiﬁcant increase in the enzy-
matic activity (Figure 2A) and production of a larger
proportion of the faster-migrating protein (Figure 2B).
ENPP1 has been shown to have an important role in the
generation and disposition of inorganic pyrophosphate
(PPi).8,17 Inactivating mutations in ENPP1 have previously
been reported to cause generalized arterial calciﬁcation of
infancy (GACI),16 and inactivation of ENPP1 in mice
results in ectopic calciﬁcation of joints and ligaments.18,19
The mutation in our hypophosphatemic patients reduces
the activity to about 4% of that of the normal enzyme,
similar to the range of activities measured for the muta-
tions causing GACI16 and resides in the same nuclease-
like domain. Speciﬁcally, the adjacent mutation
K905fsX920 was identiﬁed in a severe compound-hetero-
zygous GACI patient who died at 45 days of age16.
However, we speculate that our patients do not show
GACI because of the hypophosphatemia. Alternatively,
some in vivo ‘‘leakiness’’ enabling the production of
some PPi may save these patients from the calciﬁcations
observed in GACI. ENPP1 has also been demonstrated to
have a role in additional aberrant calciﬁcation conditions,
such as chondrocalcinosis caused by deposition of calcium
PPi dehydrate crystals.20
Previous studies on human mutants of ENPP1 have
found a variable and incomplete reciprocal association
between aberrant calciﬁcation and hypophosphatemic
rickets16,21. Because hypophosphataemia can compensate
for GACI, it has been argued that this reﬂects a physiolog-
ical compensation mechanism rather than a primary
defect.16,21 But unlike previous mutations, the Y901S
mutation in our patients results in a phenotype withThe Americacomplete dissociation between GACI and ARHR, making
a compensatory mechanism an unlikely explanation in
this case. At present, we have no explanation, but our
results suggest a previously unreported mechanism in the
generation of ARHR, maybe via the common FGF23
pathway. A direct effect of ENPP1 on Pi reabsorption may
seem unlikely, given that ENPP1 was demonstrated to
reside in the distal convoluted tubule of the murine
kidney,22 whereas most Pi reabsorption occurs in the
proximal tubule. The closely related ENPP2 is known to
have an important additional activity as lysophospholi-
pase D, which explains its biological effects on chemotaxis
and angiogenesis.23,24 The sequences immediately sur-
rounding the active site of ENPP1 and ENPP2 are very
similar, and the difference in speciﬁcity may reside else-
where. The separation of GACI and ARHR in different
mutations that have in common the loss of ENPP1 activity
may suggest that, like ENPP2, ENPP1 may have more than
one important biological activity.Supplemental Data
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